Literature DB >> 30614559

Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab.

Takayoshi Komatsu-Fujii1, Motoo Nomura2, Atsushi Otsuka1, Yoshihiro Ishida1, Keitaro Doi2, Shigemi Matsumoto2, Manabu Muto2, Kenji Kabashima1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30614559     DOI： 10.1111/1346-8138.14763

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  5 in total

1.  Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.

Authors:  Olivia Beaudoux; Jean-Baptiste Oudart; Laurence Riffaud; Laetitia Visseaux; Aude Marchal; Anne-Sophie Lebre; Florent Grange
Journal:  Mol Diagn Ther       Date:  2022-02-23       Impact factor: 4.074

2.  Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.

Authors:  Anne Fröhlich; Friederike Hoffmann; Dennis Niebel; Eva Egger; Guido M Kukuk; Marieta Toma; Judith Sirokay; Thomas Bieber; Jennifer Landsberg
Journal:  Front Oncol       Date:  2020-05-08       Impact factor: 6.244

3.  Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion.

Authors:  Laurence Pincet; Karma Lambercy; Philippe Pasche; Martin Broome; Sofiya Latifyan; Antoine Reinhard
Journal:  Front Surg       Date:  2021-01-20

Review 4.  Current Status and Prospects of Immunotherapy for Gynecologic Melanoma.

Authors:  Mayuka Anko; Yusuke Kobayashi; Kouji Banno; Daisuke Aoki
Journal:  J Pers Med       Date:  2021-05-12

5.  Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina.

Authors:  Christoph Wohlmuth; Iris Wohlmuth-Wieser; Stéphane Laframboise
Journal:  J Low Genit Tract Dis       Date:  2021-04-01       Impact factor: 3.842
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.